Kevin M Lin

US Patent:

7523973, Apr 28, 2009

Filed:

Aug 8, 2007

Appl. No.:

11/835591

Inventors:

Kevin Lin - Berkeley CA, US
Jorge Robles - Stockton CA, US
Jessica A. Scott - Dublin CA, US

Assignee:

The Clorox Company - Oakland CA

International Classification:

A01K 29/00
B07B 1/02

US Classification:

294 13, 294 55, 209418

Abstract:

The present invention provides a thermoformed litter scoop comprising a generally concave scoop portion, and a handle portion attached to the scoop portion. The scoop portion has a bottom, sides and a rear and a plurality of openings therein. The openings are defined to allow the passage of litter granules therethrough. The handle portion has reinforcing ribs and the scoop portion has reinforcing ribs. The invention also describes a method of making a thermoformed scoop.

US Patent:

20090238498, Sep 24, 2009

Filed:

Mar 18, 2008

Appl. No.:

12/050426

Inventors:

Kevin Lin - Berkeley CA, US

International Classification:

B65D 33/00

US Classification:

383105

Abstract:

Provided is a compaction package that includes a flexible film portion and a heat shrink film portion coupled to part of the flexible film portion. The compaction package has a bottom, a sidewall, and an open top that together define a hollow interior space adapted to receive and contain a granular material. In a first configuration prior to exposure to a heat source sufficient to raise the temperature of the compaction package to a certain critical heat shrink temperature, the interior space of the compaction package has a first volume. In a second configuration after exposure to the heat source, the interior space of the compaction package has a second volume that is less than the first volume.

US Patent:

20180163271, Jun 14, 2018

Filed:

Jan 14, 2015

Appl. No.:

15/104684

Inventors:

- Boulder CO, US
Kevin Lin - San Mateo CA, US

International Classification:

C12Q 1/6886
A61P 35/00
A61K 31/55

Abstract:

In one embodiment, the subject invention relates to a method for treatment of a breast or ovarian cancer patient that includes receiving assay results stating that the patient's tumor exhibits LOH, and administering a PARP inhibitor. In one embodiment, the subject invention comprising: classifying said cancer patient, with the computer system, as being likely to respond to a PARP inhibitor if the data comprises i) one or more deleterious mutations in BRCA1 or BRCA2, or ii) a percentage of the genome having greater than 10 percent LOH as determined by the sum of the lengths of each individual LOH region divided by the total genome length, wherein an LOH region is defined as the presence of homozygosity at multiple contiguous single nucleotides, but excludes whole chromosome or chromosome arm LOH.